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CD154-Dependent Priming of Diabetogenic
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Antigen-Presenting Cells
et al., 1998). Since CD154/CD40 interactions are critical
for T-T collaboration and APC-driven T cell differentia-
tion, CD154-deficient mice cannot mount primary CD4
T cell responses to exogenous antigens (Grewal et al.,
1996) or CD8CTL responses against viruses (van Essen
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et al., 1995; Yang and Wilson, 1996). Although T helper-Julia McFarlane Diabetes Research Center
dependent CD8 T cell responses require the presenceThe University of Calgary
of CD154 molecules on CD4 T cells, the contributionFaculty of Medicine
of CD8 T cells’ CD154 molecules to their own activation3330 Hospital Drive N.W.
and differentiation is poorly understood (Roy et al., 1993;Calgary, Alberta, T2N 4N1
Hermann et al., 1995; Sad et al., 1997; Lefrancois et al.,Canada
1999).
Notwithstanding the fact that most of the biological
effects of CD154/CD40 interactions can be accountedSummary
for by the activation of APCs by CD40 ligation, CD154
has the capacity to transduce intracellular signals andWe followed the fate of Kd- or I-Ag7-restricted  cell-
elicit T cell responses. CD40 cDNA-transfected tumorautoreactive T cells in monoclonal TCR-transgenic NOD
cells and agonistic anti-CD154 mAbs, for example, canmice expressing or lacking CD154. 8.3-NOD.RAG-2//
trigger proliferation, cytokine production, and/or apo-CD154/ mice, which bear autoreactive CD8 T cells,
ptosis in resting human T cells (Cayabyab et al., 1994;developed diabetes with the same incidence and
Peng et al., 1996; Blair et al., 2000). In addition, ligationtempo as 8.3-NOD.RAG-2//CD154 mice. Recruit-
of CD154 in Jurkat cells can induce c-Jun NH2 terminalment of CD154/ 8.3-CD8 CTL was accelerated by
kinase (JNK) and p38 mitogen-activated protein (MAP)CD154CD4 T cells, by expression of a B7.1 transgene
kinase (Brenner et al., 1997; Koppenhoefer et al., 1997).in  cells or by treatment of the mice with CpG-DNA
Despite these observations, it has been difficult to disso-or an agonistic anti-CD40 antibody. In contrast, the
ciate the effects of CD40-induced activation of APCsautoreactive CD4 T cells maturing in 4.1-NOD.RAG-
on T cell responses from those mediated by CD154-2/ mice lost their diabetogenic potential if they lacked
transduced T cell signaling. As a result, the true biologi-CD154, even in the presence of CD154CD4 T cells,
cal significance of CD154 triggering in vivo remains un-B7.1 molecules on  cells, CpG-DNA treatment, or
clear.
systemic CD40 ligation. These results demonstrate the
Development of spontaneous autoimmune diabetes in
existence of a novel, CD154-dependent pathway of nonobese diabetic (NOD) mice is the result of a complex
CD4 T cell activation that is independent of CD40- CD4 and CD8 T cell-dependent autoimmune process
mediated activation of APCs. against the pancreatic  cells (Delovitch and Singh,
1997).  cell-reactive CD8 T cells are invariably present
Introduction in the islets of prediabetic NOD mice (Nagata et al.,
1994; Santamaria et al., 1995; DiLorenzo et al., 1998;
The interaction between CD40 on professional APCs (B Wong et al., 1999) and play critical roles both in the
cells, dendritic cells, or macrophages) and CD154 (CD40 initiation of insulitis and in its progression toward overt
ligand) on CD4 T helper cells plays a critical role in the clinical disease (Katz et al., 1993; Serreze et al., 1994;
activation and differentiation of precytotoxic T lympho- Wicker et al., 1994; Verdaguer et al., 1996, 1997; Wang
cyte precursors (Stout and Suttles, 1996; Grewal and et al., 1996; Amrani et al., 2000a). The recruitment, acti-
Flavell, 1998). Ligation of CD40 on dendritic cells (DCs), vation, and differentiation of diabetogenic CD8 T cells,
for example, upregulates the expression of costimula- however, require the assistance of CD4 T cells. Thus,
splenic CD8T cells from diabetic NOD mice cannot accu-tory molecules, increases DC survival, and elicits the
mulate in pancreatic islets of irradiated NOD mice orproduction of proinflammatory cytokines by these cells
NOD.scid mice in the absence of CD4 T cells (Thivolet(Caux et al., 1994; Cella et al., 1996; den Haan and Bevan,
et al., 1991; Christianson et al., 1993). Furthermore, 2000; Grewal and Flavell, 1998; Stout and Suttles, 1996).
cells do not express costimulatory molecules and henceThese changes endow antigen-loaded APCs with the
cannot directly drive the differentiation of naive  cell-ability to costimulate antigen-specific CD8 and CD4
reactive CD8 T cells into CTL (Stephens and Kay, 1995).T cell responses and to foster the T cells’ differentiation
In addition, genetic susceptibility and resistance to in-into cytotoxic T lymphocytes (CTL) (van Essen et al.,
sulitis and diabetes are profoundly affected by polymor-1995; Grewal et al., 1995, 1996; Yang and Wilson, 1996;
phisms of MHC class II genes (Tisch and McDevitt,Ridge et al., 1998; Schoenberger et al., 1998; Bennett
1996), which control the development and function of
CD4 but not CD8 T cells.
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pletely prevents the onset of insulitis (Balasa et al., 1997;3Present address: Immunology Unit, Hospital Universitari Germans
Green et al., 2000), suggesting that CD40/CD154 inter-Trias i Pujol, Carretera del Canyet s/n 08916 Badalona, Barcelona,
Spain. actions play a critical role in the development, recruit-
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ment, and/or activation of diabetogenic CD4 and/or When compared to 4.1-NOD mice, however, 4.1-
NOD.CD154/ mice developed a significantly reducedCD8 T cells. Here we have investigated the role of
CD154 in the recruitment, activation, and differentiation incidence (and delayed onset) of both diabetes (Figure
2B) and insulitis (Figure 2C). The few T cells that wereof two NOD islet-derived, highly diabetogenic, MHC
class I- or class II-restricted  cell-reactive T cell speci- present in islets of 4.1-NOD.CD154/ mice produced
Th1 cytokines upon stimulation with phorbol-myristateficities (8.3-CD8 and 4.1-CD4, respectively) in TCR-
transgenic, recombination-activating gene (RAG)-2- acetate and ionomycin (Figure 2D). This suggested that
the CD154 deficiency impaired the diabetogenic activitydeficient NOD mice. We show that unlike 8.3-CD8 T
cells, which do not require CD154 on their surface to of 4.1-CD4 T cells by interfering with their recruitment,
rather than by inducing their immune deviation. Thisproliferate in pancreatic lymph nodes, to spontaneously
differentiate into CTL in vivo, and to trigger diabetes, 4.1- inefficient recruitment of 4.1-CD4 Th1 cells in 4.1-
NOD.CD154/ mice was not due to absence of autoanti-CD4 T cells cannot respond to  cell antigen in vivo
in the absence of CD154. Constitutive expression of gen-loaded APCs inside islets, as purified 4.1-CD4 T
cells proliferated efficiently in response to NOD.CD154/costimulatory molecules on  cells and activation of
professional APCs in vivo with CD154 CD4 T helper  islet cells in the absence of exogenous APCs (Figure
2E). Thus, in the absence of CD154, 4.1-CD4 T cellscells, CpG DNA, or agonistic anti-CD40 mAb potentiates
the diabetogenic potential of CD154-deficient 8.3-CD8 can respond to antigen in vitro but do not efficiently
accumulate in pancreatic islets in vivo.T cells but has no effect on the diabetogenicity of
CD154-deficient 4.1-CD4 T cells. These data indicate
that CD154 triggering is indispensable for the activation Complete Absence of Insulitis and Diabetes
of naive autoreactive CD4 T cells in spontaneous auto- in Monoclonal CD154-Deficient 4.1-NOD Mice
immune diabetes and thus demonstrate the existence To confirm that the diabetes resistance of 4.1-
of a novel, CD154-dependent pathway of CD4 T cell NOD.CD154/ mice was due to poor recruitment of
activation in vivo that is independent of CD40-mediated 4.1-CD4 T cells as opposed to immune regulation by
activation of APCs. nontransgenic T cells, we compared the natural history
of diabetes in 4.1-NOD.RAG-2//CD154 versus 4.1-
NOD.RAG-2//CD154/ mice, which cannot rearrangeResults
endogenous TCR genes (Verdaguer et al., 1997). 4.1-
NOD.RAG-2//CD154 mice developed diabetes withCD154-Deficient 4.1-CD4 T Cells Respond to Antigen
an incidence and tempo similar to 4.1-NOD mice, butStimulation In Vitro but Cannot Efficiently Trigger
none of 47 4.1-NOD.RAG-2//CD154/ mice developedDiabetes In Vivo
diabetes (Figure 3A). Histopathological studies con-To investigate whether CD40/CD154 interactions are
firmed that, unlike their CD154 counterparts, 4.1-necessary for the development and/or activation of dia-
NOD.RAG-2//CD154/ mice were insulitis free (Figurebetogenic CD4 T cells, we compared the fate of a
3B). Thus, CD154 is indispensable for the recruitmenthighly diabetogenic CD4 T cell specificity in CD154-
and/or accumulation of 4.1-CD4 T cells into islets.competent versus CD154-deficient NOD mice express-
ing TCR transgenes derived from an islet-derived
CD4 T cell clone (4.1-NOD and 4.1-NOD.CD154/ Diabetogenic CD8 T Cells Do Not Need to Express
CD154 to Trigger Autoimmune Diabetesmice, respectively) (Schmidt et al., 1997). Expression of
the 4.1-TCR in 4.1-NOD mice skews thymocyte develop- Development of autoimmune diabetes in wild-type NOD
mice is CD8 T cell dependent (Katz et al., 1993; Serrezement toward the CD4 T cell subset and results in a
dramatic acceleration of the onset of diabetes, owing et al., 1994; Wicker et al., 1994; Wang et al., 1996; Verda-
guer et al., 1996, 1997; Amrani et al., 2000a). To ascertainto massive recruitment of  cell-cytotoxic CD4 T cells
into islets (Schmidt et al., 1997; Amrani et al., 2000b). whether diabetogenic CD8 T cells also need to express
CD154 to differentiate into CTL in vivo, we compared4.1-NOD.CD154/ mice displayed thymic, splenic, and
lymph node cytofluorometric profiles that were compa- the fate of a diabetogenic, H-2Kd-restricted  cell-reac-
tive TCR (8.3) in CD154-competent versus CD154-defi-rable to those seen in 4.1-NOD mice (Figure 1) and ex-
ported  cell-reactive CD4 T cells to the periphery (Fig- cient 8.3-TCR-transgenic NOD.RAG-2/ mice. The 8.3-
TCR recognizes the peptide NRP-A7 and uses a TCRure 2A). Although the mean fluorescence intensity for
V11 on CD154/ thymocytes was slightly lower than chain that is identical to those used by a significant
fraction of autoreactive CD8 T cells recruited to isletson CD154 thymocytes, the differences did not reach
statistical significance (99  40 versus 115  33 for during the earliest stages of insulitis (Anderson et al.,
1999; DiLorenzo et al., 1998; Amrani et al., 2000a). WeCD4CD8 cells; 92 5 versus 104 16 for CD4CD8
cells). The peripheral CD4 T cells of both types of mice have shown that naive 8.3-CD8 T cells are significantly
more diabetogenic in the presence of CD4 T cells thanalso expressed comparable levels of V11 (mfi values:
60  2 for CD154/ cells; 65  6 for CD154 cells). in their absence. However, the requirement for CD4 T
Figure 1. Development of CD154 and CD154/ 4.1-CD4 T Cells
CD4, CD8, and V11 profiles of thymocytes (A) and splenocytes (B) from 4.1-NOD (n  12) and 4.1-NOD.CD154/ mice (n  9). Cells were
stained with anti-CD8-PE, anti-V11-FITC, and anti-CD4-biotin plus Streptavidin-PerCP. Numerical values correspond to percentage  SD
of cells within each gate. None of the differences were statistically significant.
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Figure 2. Function of CD154 and CD154/ 4.1-CD4 T Cells In Vitro and In Vivo
(A) Proliferation of naive splenic 4.1-CD4 T cells from 4.1-NOD and 4.1-NOD.CD154/ mice against irradiated NOD islet cells.
(B) Natural history of diabetes in female 4.1-NOD (n  225) and 4.1-NOD.CD154/ mice (n  62).
(C) Insulitis scores in 20-week-old 4.1-NOD (n  6) versus 4.1-NOD.CD154/ mice (n  7).
(D) Cytokine profile of islet-associated T cells in 20-week-old 4.1-NOD (n  4) versus 4.1-NOD.CD154/ mice (n  6).
(E) Proliferation activity of splenic 4.1-CD4 T cells from 4.1-NOD against NOD and NOD.CD154/ islet cells.
cells is not absolute and, as a result, over 40% of 8.3- ated equally well (Figure 5A), secreted similar levels of
cytokines (IFN- and IL-2) (Figure 5B), and differentiatedNOD.RAG-2/ mice spontaneously develop diabetes
(Verdaguer et al., 1997). 8.3-NOD.RAG-2/ and 8.3- efficiently into CTL in response to NRP-A7 peptide-
pulsed bone marrow-derived DCs (Figures 5C and 5D).NOD.RAG-2//CD154/ mice displayed similar thymo-
cyte and splenocyte cytofluorometric profiles (Figure 4). In fact, CTL from both types of mice killed both Fas-
expressing (Figure 5C) and Fas-deficient fibroblastsThe splenic CD8 T cells of both types of mice prolifer-
Figure 3. Diabetogenic Activity of CD154 and CD154/ 4.1-CD4 T Cells in Monoclonal T Cell NOD Mice
(A) Natural history of diabetes in female 4.1-NOD.RAG-2/ (n  123), 4.1-NOD.RAG-2//CD154/ mice (n 47), and 4.1/RIP-B7.1-NOD.RAG-2//
CD154/ mice (n  34).
(B) Insulitis scores in 20-week-old 4.1-NOD.RAG-2/ (n  2) and 4.1-NOD.RAG-2//CD154/ mice (n  3).
Activation of Diabetogenic CD4 Cells via CD154
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Figure 4. Development of CD154 and CD154/ 8.3-CD8 T Cells in Monoclonal T Cell NOD Mice
CD4, CD8, and V8.1/8.2 profiles of thymocytes (A) and splenocytes (B) from 8.3-NOD.RAG-2/ (n  7) and 8.3-NOD.RAG-2//CD154/ mice
(n  13). Numerical values correspond to percentage  SD of cells within each gate.
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Figure 5. Function and Diabetogenicity of CD154/ 8.3-CD8 T Cells from Monoclonal T Cell NOD Mice
(A) Proliferation of splenic CD8 T cells in response to NOD bone marrow-derived DCs pulsed with NRP-A7 or TUM (1 	M). CD8 T cells (2 
 104 )
were incubated with 5 
 103 DCs for 3 days, pulsed with [3 H]-thymidine, harvested, and counted.
(B) Cytokine secretion by 8.3-CD8 T cells in response to peptide-pulsed DCs.
(C and D) Cytotoxicity of NRP-A7-differentiated 8.3-CD8 T cells against NRP-A7- or TUM-pulsed targets (L1210-Fas or L1210-Fas). Splenic
8.3-CD8 T cells were challenged with NRP-A7-pulsed DCs as in (A) and expanded in the presence of rIL-2 for 4 additional days. The cells were
used as effectors in 51Cr-release assays at a 1:10 target:effector ratio. Bars show the standard error of the means.
(E) Cumulative incidence curves of diabetes in female 8.3-NOD.RAG-2//CD154 (n  106), 8.3-NOD.RAG-2//CD154/ mice (n  63), and 8.3-
NOD.RIP-B7.1/RAG-2//CD154/ mice (n  18).
(Figure 5D). Unexpectedly, 8.3-NOD.RAG-2//CD154/ press CD154 to undergo antigen-driven activation and
proliferation in the pancreatic lymph nodes.mice developed diabetes with the same incidence and
kinetics as 8.3-NOD.RAG-2//CD154 mice (Figure 5E),
indicating that, unlike 4.1-CD4 T cells, 8.3-CD8 T cells
Constitutive Expression of Transgenic B7.1 Moleculesdo not need to express CD154 to differentiate into diabe-
in  Cells Enhances the Diabetogenic Activity oftogenic effectors in vivo.
CD154-Deficient 8.3-CD8 but Not 4.1-CD4 T Cells
To ascertain whether CD154-deficient 4.1-CD4 T cells
did not trigger diabetes because they were unable toCD154-Deficient 4.1-CD4 T Cells Cannot Recognize
Antigen in the Pancreatic Lymph Nodes of NOD Mice elicit costimulatory activity in APCs, we studied the his-
tory of diabetes in 4.1-NOD.RAG-2//CD154/ and 8.3-Recruitment of diabetogenic T cells into islets is pre-
ceded by recognition of islet antigen on professional NOD.RAG-2//CD154/ mice expressing a rat-insulin
promoter (RIP) B7.1 transgene in  cells (Guerder et al.,APCs in the pancreatic lymph nodes (Hoglund et al.,
1999). To determine whether CD154-deficient 4.1-CD4 1994). B7.1 molecules have costimulatory activity on
CD8 and CD4 T cells both when provided in cis (i.e.,T cells could undergo antigen-induced activation in vivo,
we compared the ability of CD154and CD154/, CFSE- when expressed on the antigen-loaded APC itself) and
in trans (i.e., when expressed on bystander, nonantigen-labeled 4.1-CD4 T cells and 8.3-CD8 T cells to prolifer-
ate in the peripheral lymphoid organs of nondiabetic bearing APCs) (Ding and Shevach, 1994; Mandelbrot
et al., 2001). Whereas non-TCR-transgenic RIP-B7.1-NOD hosts. CD154 4.1-CD4 T cells, CD154 8.3-CD8
T cells, and CD154/ 8.3-CD8 T cells underwent sev- NOD.RAG-2//CD154/ mice did not develop diabetes
(n  0/27), expression of RIP-B7.1 molecules on  cellseral rounds of cell division exclusively in the pancreatic
lymph nodes (Figure 6A). In contrast, CD154/ 4.1-CD4 of 8.3-NOD.RAG-2//CD154/ mice dramatically in-
creased the incidence of diabetes and accelerated itsT cells did not proliferate at all at this site (Figure 6A).
Furthermore, whereas CD154 4.1-CD4 T cells upregu- onset (Figure 5E). Since most of the 8.3-NOD.RAG-2/
mice that do not develop diabetes are also insulitis free,lated both CD69 and CD44 in the pancreatic lymph
nodes of the hosts within 6 days of transfer, CD154/ the above results indicated that presence of B7.1 mole-
cules on  cells was somehow able to promote the4.1-CD4 T cells did not (Figures 6B and 6C). Thus,
unlike 8.3-CD8 T cells, 4.1-CD4 T cells need to ex- accumulation of 8.3-CD8 T cells in islets. Expression
Activation of Diabetogenic CD4 Cells via CD154
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Figure 6. CD154-Dependent Activation of 4.1-CD4 T Cells in the Pancreatic Lymph Nodes of NOD Mice and Costimulation of In Vitro 4.1-CD4
T Cell Responses by CD154
(A) Naive splenic T cells from the corresponding transgenic mice were labeled with CFSE and injected i.v. into NOD hosts. The hosts were sacrificed
6 days later, and their pancreatic lymph nodes were examined for the presence of proliferating CFSE T cells by flow cytometry.
(B and C) Fluorescence intensity for CD69 and CD44 on CD154 4.1-CD4 versus CD154/ 4.1-CD4 CFSE-labeled cells in the pancreatic (PLN)
and mesenteric lymph nodes (MLN) 6 days after transfer into NOD hosts (n  3–9 mice/group).
(D) Proliferation of and cytokine secretion by splenic CD4 T cells (2 
 105 ) from 4.1-NOD and 4.1-NOD.CD154/ mice in response to Dynabeads
coated with anti-CD154 (56.7 ng/6 
 105 beads) and/or anti-CD3 mAbs (0.28 ng/6 
 105 beads) mAbs. The cultures were pulsed with [3 H]-
thymidine at 48 hr and harvested 18 hr later. The cytokine contents in the supernatants were evaluated at 48 hr.
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of the RIP B7.1 transgene in 4.1-NOD.RAG-2//CD154 NOD.RAG-2//CD154/ mice (Group 15 in Table 1), it
did not promote diabetogenesis when compared to un-mice also increased the incidence of 4.1-CD4 T cell-
induced diabetes (from 68% to 100%; data not shown). treated and anti-B220 mAb-treated controls (Table 1,
Groups 11 and 16, respectively).In contrast, none of the 34 4.1/RIP-B7.1-NOD.RAG-2//
CD154/ mice that were followed developed diabetes
(Figure 3A). Adoptive transfer experiments of in vitro- Systemic Activation of APCs with Bacterial CpG DNA
Accelerates Diabetogenesis in 8.3-NOD.RAG-2//activated, B7-expressing DCs into mice followed by
agonistic anti-CD40 mAb and/or CpG DNA treatment CD154/ but Not 4.1-NOD.RAG-2//CD154/ Mice
CpG oligodeoxynucleotides bind to the Toll-like Recep-confirmed that this was not the result of inadequate
exposure of 4.1-CD4 T cells to B7 molecules on islet tor 9 on DCs, B cells, and macrophages, inducing their
activation (Hemmi et al., 2000). To determine whethercells (see below). Therefore, expression of costimulatory
B7.1 molecules on cells can promote the accumulation systemic activation of APCs with CpG DNA could uncou-
ple 4.1-CD4T cell activation from CD154, we comparedof CD154-deficient 8.3-CD8 T cells and CD154-compe-
tent 4.1-CD4 T cells in islets but cannot drive the re- the effects of CpG DNA on the natural history of diabetes
in 8.3-NOD.RAG-2//CD154/ and 4.1-NOD.RAG-2//cruitment of CD154-deficient 4.1-CD4 T cells to the site.
CD154/ mice. CpG DNA clearly enhanced the diabeto-
genic potential of CD154/ 8.3-CD8 T cells (Table 1,CD154-Deficient 4.1-CD4 T Cells Cannot Respond to
CD4 T Cell-help Group 4) but was unable to restore the diabetogenic
potential of CD154/ 4.1-CD4 T cells, even when givenSplenic CD4 T cells from prediabetic NOD mice signifi-
cantly enhance the diabetogenic activity of naive 8.3- in combination with NOD splenic CD4 T cells (Table 1,
Groups 14 and 13, respectively). This inability of CpGCD8 T cells upon adoptive transfer into 8.3.NOD.RAG-
2/ hosts (Verdaguer et al., 1997). To determine whether and FGK45 to elicit the activation of CD154/ CD4 T
cells in vivo was confirmed by treatment of the miceCD154/ 8.3-CD8 and CD154/ 4.1-CD4 T cells can
respond to exogenous T cell help, we transfused CD4 with both activated DCs plus FGK45 and/or CpG DNA.
Whereas all the 4.1-NOD.RAG-2//CD154 mice thatsplenocytes from wild-type NOD mice into NOD.RAG-
2//CD154, 8.3-NOD.RAG-2//CD154/, and 4.1- received activated DCs and CpG developed diabetes
within 2 days after the first injection, diabetes did notNOD.RAG-2//CD154/ hosts. NOD CD4 splenocytes
did not even induce insulitis in lymphocyte-deficient develop in any of 6 4.1-NOD.RAG-2//CD154/ mice
that received two doses of the same treatment (Group 10NOD.RAG-2//CD154 females (Group 7 in Table 1) but
significantly increased the incidence of diabetes in 8.3- versus 17 in Table 1). Furthermore, these mice remained
diabetes free for at least 3 weeks following two consecu-NOD.RAG-2//CD154/ mice (Groups 2 and 3 in Table
1). This T helper effect was CD154 dependent, since tive i.p. injections of FGK45 mAb given 6 weeks after
the first DCCpG injection.it did not occur in 8.3-NOD.RAG-2//CD154/ hosts
that were transfused with splenic CD4 T cells from
NOD.CD154/ donors (data not shown). In contrast, Costimulation of In Vitro 4.1-CD4 T Cell Responses
by CD154while adoptively transferred 4.1-NOD.RAG-2//
CD154/ mice developed mild peri-insulitis, they re- It has been shown that CD154 has the potential to co-
stimulate the proliferative and cytokine secretion activitymained diabetes free for at least 10 weeks after transfer
(Group 12 in Table 1). These results thus indicated that, of human CD4 T cells in vitro (Blair et al., 2000). In
addition, ligation of CD154 on human Jurkat T cells andunlike CD154/ 8.3-CD8 T cells, CD154/ 4.1-CD4 T
cells cannot respond to autoantigen-loaded APCs acti- mouse splenic T cells induces the activation of both
JNK1 and p38 MAPK (Brenner et al., 1997), which playvated by trans CD154 signals.
critical roles in T cell proliferation and cytokine produc-
tion (Kane et al., 2000). To determine whether CD154CD40 Crosslinking In Vivo Triggers Diabetes
in 8.3-NOD.RAG-2//CD154/Mice but Not signaling costimulates 4.1-CD4 T cell responses, we
tested the ability of CD154 crosslinking to potentiatein 4.1-NOD.RAG-2//CD154/Mice
CTL responses against viruses are impaired in CD154/ the agonistic activity of suboptimal concentrations of
anti-CD3mAb coated on beads. Anti-CD154 enhancedmice but develop normally upon treatment of the mice
with agonistic anti-CD40 mAbs, indicating that CD40 the ability of anti-CD3 mAb to trigger the proliferation
and the secretion of IFN- by 4.1-CD4 T cells (Figurecrosslinking can overcome the need for CD154 in the
generation of CTL responses in vivo (Bennett et al., 1998; 6D). No significant differences in IL-2 secretion were
noted. These effects were CD154-dependent as theyRidge et al., 1998; Schoenberger et al., 1998). To deter-
mine whether ligation of CD40 on APCs could enhance were not seen with CD154/ 4.1-CD4 T cells (Figure
6D). Thus, as previously proposed for human T cells,the diabetogenic activity of CD154/ 8.3-CD8 T cells
and/or restore the diabetogenic potential of CD154/ 4.1- CD154 can costimulate murine 4.1-CD4 T cell re-
sponses in vitro.CD4 T cells, we treated 8.3-NOD.RAG-2//CD154/ and
4.1-NOD.RAG-2//CD154/ mice with the agonistic
anti-CD40 mAb FGK45. FGK45 mAb treatment dramati- Discussion
cally increased the incidence of diabetes in 8.3-
NOD.RAG-2//CD154/ mice when compared to un- Diabetogenesis results from well-orchestrated, but ill-
defined, collaborations between autoreactive CD4 andtreated or anti-B220 mAb-treated controls (Table 1,
Groups 5, 2, and 6, respectively). In contrast, although CD8 T cells and professional APCs (Delovitch and
Singh, 1997). Previous studies have shown that CD154-FGK45 treatment increased the severity of insulitis in 4.1-
Immunity
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deficient NOD mice are completely resistant to both by CD4 T helper cells (den Haan and Bevan, 2000) can
bypass the requirement for CD154 engagement. Thus,diabetes and insulitis, suggesting a role for CD154/CD40
interactions in the initiation of the disease process when taken together, these data show that CD154 trig-
gering is indispensable for the activation of 4.1-CD4 T(Green et al., 2000). Here we have investigated the role
of CD154/CD40 interactions and APC activation in the cells.
Crosslinking of CD154 potentiated in vitro 4.1-CD4recruitment of diabetogenic CD4 and CD8 T cells in
spontaneous autoimmune diabetes, using disease-rele- T cell responses induced by suboptimal concentrations
of anti-CD3 mAb in a CD154-dependent manner, indicat-vant, informative reductionist systems. Our results dem-
onstrate that, despite the existence of CD154-indepen- ing that CD154 can indeed deliver intracellular signals
in 4.1-CD4 T cells. This is in agreement with previousdent pathways of APC activation and T-T collaboration
in vivo (Bachmann et al., 1999; Green and Flavell, 1999; in vitro studies that supported a costimulatory role for
CD154 signaling in both human and murine T cells. Anti-Ruedl et al., 1999; Lu et al., 2000), CD154 triggering is
a key event in the activation of diabetogenic CD4 (but CD154 mAbs, for example, potentiate anti-CD3-induced
proliferation of human CD4 T cells in vitro (Blair et al.,surprisingly not CD8) T cells. Importantly, the data
show that the inability of CD154-deficient 4.1-CD4 T 2000; Blotta et al., 1996), induce expression of CD54
and CD44H (Shinde et al., 1996; Gurunathan et al., 1998),cells to trigger diabetes cannot be overcome by strate-
gies that bypass the need for CD40 ligation and thus and elicit production of IFN-, TNF, and IL-10 by these
T cells (Blair et al., 2000). Furthermore, ligation of CD154demonstrate the existence of a novel, CD154-depen-
dent pathway of CD4 T cell activation that is indepen- on both human and mouse T cells induces the activation
of both JNK1 and p38 MAPK (Brenner et al., 1997), whichdent of CD40-mediated activation of APCs.
Abrogation of CD154 expression rendered 4.1-CD4 are involved in signal integration and cytokine produc-
tion during T cell costimulation (Kane et al., 2000). TheT cells unable to proliferate against islet antigen in the
pancreatic lymph nodes and hence to accumulate in fact that 4.1-CD4 T cells can neither proliferate nor
upregulate activation markers in vivo in the absence ofislets, without impairing their positive selection in the
thymus or their ability to proliferate in response to islet CD154 is consistent with all of these in vitro observations
and provide a mechanistic explanation for the completeantigen ex vivo. This inability of CD154/ 4.1-CD4 T
cells to trigger insulitis is reminiscent of the inability resistance of 4.1-NOD.RAG-2//CD154/ mice to dia-
betes development. Furthermore, they account for theof myelin basic protein (MBP)-specific TCR-transgenic
CD154/ CD4 T cells to undergo priming in antigen- inability of transgenic RIP-B7.1 molecules, in vitro-acti-
vated DCs, agonistic anti-CD40 mAb, and CpG DNA tochallenged mice despite being able to proliferate in re-
sponse to MBP in vitro (Grewal et al., 1996). However, induce the activation of CD154/ 4.1-CD4 T cells in
our system. Whether ligation of CD154 contributes tothe underlying mechanisms appear to be different.
Whereas CD154/ MBP-reactive CD4 T cells primed the recruitment of effector 4.1-CD4 T cells by inducing
some of the responses described above remains to beefficiently in the presence of B7.1 APCs (Grewal et al.,
1996), CD154/ 4.1-CD4 T cells remained quiescent in determined but, with the exception of IL-10 (Moritani et
al., 1996), they are all good candidates. Although anti-mice transfused with TNF/LPS-activated DCs, in mice
expressing B7.1 molecules on  cells, or in mice treated CD3/CD154 crosslinking in human T cells in vitro ulti-
mately results in apoptosis (Blair et al., 2000), ligationwith potent DC activators. CpG DNA and agonistic anti-
CD40 mAbs induce costimulatory activity on DCs and/or of CD154 on 4.1-CD4 T cells in vivo does not occur in
isolation and thus its proapoptotic effect in human Tuncouple CD8 T cell activation and CTL differentiation
from the need of CD4 T helper cells in different models cells in vitro is likely to be overridden by other costimula-
tory signals.(Bennett et al., 1998; Ridge et al., 1998; Schoenberger
et al., 1998; Schuurhuis et al., 2000). Furthermore, they 8.3-CD8 T cells do not efficiently accumulate into
pancreatic islets in the absence of CD4 T cells (Verda-promote the migration of antigen-loaded DCs into drain-
ing lymph nodes (Moodycliffe et al., 2000) and elicit the guer et al., 1997). However, 8.3-CD8 T cells trigger a
delayed, T helper-independent form of diabetes in 8.3-production of high levels of IL-12 by these cells (Cella
et al., 1996; Koch et al., 1996; Hemmi et al., 2000). Both NOD.RAG-2/ mice and thus their reliance on CD4 T
helper cells is not absolute (Verdaguer et al., 1997). DataCpG DNA and agonistic anti-CD40 mAb dramatically
enhanced the pathogenicity of CD154/ 8.3-CD8 T shown here have indicated that although CD154/CD40
interactions are indispensable for the activation of 4.1-cells but were surprisingly ineffective at modifying the
pathogenicity of CD154/ CD4 cells, even in the pres- CD4 T cells and for the T helper-dependent activation
of 8.3-CD8 T cells, they are totally dispensable for theence of CD154-competent CD4 T helper cells. Splenic
CD4 T cells from prediabetic NOD mice (containing CD4 T cell-independent diabetogenic activity of 8.3-
CD8 T cells. Although surprising, this was not a totallyautoreactive T helper cells) potentiate the insulitogenic
activity of CD154/ 8.3-CD8 T cells in a CD154-depen- unexpected observation, as CD8 T cells are less de-
pendent on costimulation than CD4 T cells, particularlydent manner, possibly by inducing the activation and
maturation of DCs, as in other models (Caux et al., 1994; in alloreactive and antiviral immune responses (Bach-
mann et al., 1999; Newell et al., 1999; Ruedl et al., 1999;Cella et al., 1996; Bennett et al., 1998; Borrow et al.,
1998; Ridge et al., 1998; Schoenberger et al., 1998; Buhl- Trambley et al., 1999; Kishimoto et al., 2000; Whitmire
and Ahmed, 2000). On the other hand, activation of cer-mann et al., 1999). The inability of CD4 T helper cells,
CpG DNA, and agonistic anti-CD40 mAb to activate tain CD8 T cell specificities requires the presence of
CD154 on the CD8 T cells themselves (Lefrancois etCD154/ CD4 T cells is consistent with the idea that
neither ligation of CD40 nor other APC activatory recep- al., 1999). Since 8.3-CD8 T cells can recognize islet
antigen in the pancreatic lymph nodes in the absencetors, such as TRANCE-R, 4-1BB-ligand, or OX-40-ligand
Activation of Diabetogenic CD4 Cells via CD154
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Cell Lines, Antibodies, and Flow Cytometryof CD4 T cells, our data indicate that there must be
L2120-Fas and L2120-Fas cells were from P. Goldstein (CNRS,some constitutive processing of  cell autoantigens and
Marseille, France). H-2Kd-transfected RMA-S cells (RMA-SKd) weresubsequent migration of antigen-loaded DCs to the pan-
from M. Bevan (University of Washington, Seattle, WA). The FGK45
creatic lymph nodes in the absence of a T cell-mediated (anti-CD40) hybridoma was from A. Rolink (Basel Institute for Immu-
insult. In turn, this implies that in 8.3-NOD.RAG-2// nology, Basel, Switzerland). Anti-CD8-PE (53-6.7), anti-CD4-FITC/
biotin (IM7), anti-CD69-PE (H1.2F3), anti-CD44-biotin (IM7), anti-CD154/ mice, 8.3-CD8 T cells must somehow be able
CD154 (MR1), anti-V11-FITC (RR3-15), anti-V8.1/8.2-FITC (MR5-2),to induce costimulatory activity on DCs via molecules
anti-I-Ak/g7-biotin (10-3.6), anti-CD45R/B220-biotin or -PerCP (RA36B2),other than CD154, such as TRANCE or TNF- (Bach-
anti-CD11c-biotin (HL3), anti-CD11b-biotin (M1/70), anti-B7.1-biotinmann et al., 1999; Green and Flavell, 1999; Green et al.,
(16-10A1), anti-B7.2-biotin (GL1), and anti-H-2Kd-PE (SF1-1.1) were
2000). It should be noted that 8.3-CD8 T cells secrete from PharMingen (San Diego, CA). Mouse IgG-absorbed goat anti-
abundant levels of TNF upon antigen recognition (Ver- rat IgG-FITC/biotin, and goat anti-mouse IgG-FITC and Streptavidin-
PerCP were from Caltag (San Francisco, CA) and Becton-Dickinsondaguer et al., 1997) and that TNF promotes CD154-
(San Jose, CA), respectively. Carboxyfluorescein diacetate succini-independent presentation of antigen to CD8 T cells
midyl ester (CFSE) was from Molecular Probes (Eugene, OR).(Green et al., 2000). Thus, 8.3-CD8 T cell-derived TNF
is a likely candidate as a costimulator-inducing signal.
PeptidesThe complete absence of insulitis in CD154/ NOD
The peptides NRP-A7 and TUM were prepared using FMOC chemis-and anti-CD154 mAb-treated NOD mice (Balasa et al.,
try, purified by rpHPLC to 90% purity, and sequenced by mass
1997; Green et al., 2000) has conclusively shown that spectrometry (Chiron Technologies, San Diego, CA).
CD154/CD40 interactions play a critical role in the initia-
tion of autoimmune diabetes. However, because of the Bone Marrow-Derived DCs and Islet Cells
cellular and molecular complexity of the diabetogenic Bone marrow-derived DCs were prepared by culturing bone marrow
cells in the presence of rmGM-CSF and rmIL4 (5 ng/ml) (Lutz et al.,autoimmune response in wild-type NOD mice, it has not
1999). Resulting cells were 70% CD11c, CD11b, I-Ag7, Kd,been possible to distinguish between a role for CD40-
CD40, B7.1, and B7.2. Activation of DCs for in vivo experimenta-CD154 interactions in the activation of CD4 T cells,
tion was induced by overnight culture in the presence of LPS (1 	g/CD8 T cells, and/or APCs. Our observation that CD154
ml). Mice were treated with two injections of 1–2 
 106 DCs (i.v.)
triggering is essential for the recruitment of 4.1-CD4 T and CpG DNA (10 nmoles; i.p.) 7 days apart. To prepare islet cells,
cells, coupled with the exquisite diabetogenic activity pancreatic islets were isolated by collagenase digestion of the pan-
creas, purified on Ficoll gradients, handpicked, and disrupted intoof 4.1-CD4T cells, and the CD154-dependent, T helper-
single-cell suspensions using Cell Dissociation Buffer (Gibco-BRL,assisted recruitment of CD8 T cells suggests that dia-
Gaithesburg, MD).betogenesis in wild-type NOD mice requires signaling
through CD154 on 4.1-like CD4 T cells. Although it
Generation of 8.3-CD8 CTLremains to be determined whether CD154 triggering is
Spleen cells were adjusted to 2 
 104 CD8 T cells/100 	l of RPMIinvolved in the activation of other CD4T cell responses,
1640 containing 10% heat-inactivated fetal bovine serum, stimu-
our observations support a model for the initiation of lated with NRP-A7 (0.0001 to 1 	M) or TUM-pulsed (1 	M) bone
diabetogenesis in which activation of insulitogenic CD4 marrow-derived DCs (5
 103 cells/well) for 3–4 days, and expanded
in the presence of 0.5 U/ml of rIL-2 (Takeda, Osaka, Japan) for 7–10T cells requires CD154 triggering, independently of
days. The growing cells (95% CD8 pure) were used as effectorsCD40 ligation or APC activation. This initial step would
in cytotoxicity assays.be followed by insulitis, recruitment of diabetogenic
CD8 T cells, avidity maturation (assisted by CD4 T
51Cr-Release Assayscells), and  cell destruction.
L1210-Fas and L1210-Fas cells were labeled with [51Cr]-sodium
chromate for 2 hr at 37C, washed, seeded at 104 cells per 100 	l/
Experimental Procedures well, pulsed with NRP-A7 or TUM (1 	M) for 1 hr at 37C, and used
as target cells in 51Cr-release assays. Effector cells were added to
Mice each well in duplicate at a 1:10 target:effector ratio. Plain medium
8.3-NOD.RAG-2/ and 4.1-NOD.RAG-2/ mice have been de- or 1% Triton X-100 was added to sets of target cells for examination
scribed (Verdaguer et al., 1997). RIP-B7.1-NOD.scid mice (Guerder of spontaneous and total cell lysis, respectively. The plates were
et al., 1994) were obtained from D. Serreze (The Jackson Lab, Bar incubated at 37C for 8 hr, and the supernatants were collected for
Harbor, ME). NOD.CD154/ mice were produced by backcrossing determination of specific 51Cr-release.
the CD154 mutation of C57BL/6.CD154/ mice (The Jackson Lab)
(Renshaw et al., 1994) onto NOD/Lt mice for nine generations. Mice
Proliferation and Cytokine Secretion Assays
were PCR typed for microsatellite polymorphisms linked to Idd2,
Splenic 8.3-CD8 T cells (2
 104 /well) were incubated, in duplicate,
Idd3, Idd4, Idd5, Idd7, Idd8/12, Idd9, Idd14, and Idd15 to confirm
with NRP-A7 (0.0001 to 1 	M) or TUM-pulsed (1 	M) bone marrow-
the absence of C57BL/6-derived, diabetes-protective alleles at
derived DCs (2
 104 /well) for 3 days at 37C in 5% CO2. The prolifer-known Idd loci. NOD.RAG-2//CD154/, RIP-B7.1-NOD.CD154/,
ative activity of CD154/ 4.1-CD4 T cells was assessed by culturing
8.3- or 4.1-NOD.RAG-2//CD154/, 8.3- or 4.1-NOD.RAG-2/
splenic 4.1-CD4 T cells (2 
 104 /well) with irradiated islet cells
CD154/, 8.3/RIP-B7.1-NOD.RAG-2//CD154/, and 4.1/RIP-B7.1-
from NOD or NOD.CD154/ mice (1 
 105 /well) as a source of
NOD.RAG-2//CD154/ mice were produced by intercrossing het-
antigen in the absence of exogenous APCs. Alternatively, CD4 T
erozygous and homozygous mutant/transgenic mice and by screen-
cells (2 
 105 /well) were cultured for 3 days with 0.5 	M polyure-
ing the offspring for inheritance of the transgenes and mutations
thane-coated, tosyl-activated beads coated with anti-CD154 and/
by PCR of tail DNA. All mice were housed under specific pathogen-
or an anti-CD3mAbs as per the manufacturer’s instructions (Dynal;
free conditions.
6 
 105 beads/well). In brief, 3.4 
 107 beads were incubated with
10 	g anti-CD154 and/or 0.05 	g anti-CD3 mAbs in a total volume
of 43 	l, washed, and used. The chosen concentration of anti-CD3Diabetes
Diabetes was monitored by measuring urine glucose levels with mAb corresponded to the lowest concentration that induced T cell
responses above background. Cultures were pulsed with 1 	Ci ofDiastix (Miles, Ontario, Canada) twice weekly. Animals were consid-
ered diabetic after two consecutive readings 3. [3 H]-thymidine during the last 18 hr of culture.
Immunity
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Cytokine Secretion (2000b). IL-1, IL-1, and IFN- mark beta cells for Fas-dependent
destruction by diabetogenic CD4 T lynphocytes. J. Clin. Invest.Naive splenic 8.3-CD8 T cells (2 
 104 /well) were incubated with
NRP-A7- or TUM-pulsed (1 	M) NOD DCs (5 
 103 /well), or mAb- 105, 459–468.
coated beads in 96-well plates for 48 hr at 37C. The supernatants Anderson, B., Park, B.J., Verdaguer, J., Amrani, A., and Santamaria,
(100 	l/well) were assayed for IL-2, IL-4, and/or IFN- content by P. (1999). Prevalent CD8() T cell response against one peptide/
ELISA using commercially available kits (R&D Systems, Minneapo- MHC complex in autoimmune diabetes. Proc. Natl. Acad. Sci. USA
lis, MN). 96, 9311–9316.
Bachmann, M., Wong, B., Josien, R., Steinman, R., Oxenius, A., and
Cytokine Profile of Intra-Islet T Cells
Choi, Y. (1999). TRANCE, a tumor necrosis factor family member
Freshly isolated islets and islet-associated T cells (2 
 104 ) were
critical for CD40 ligand-independent T helper cell activation. J. Exp.
activated with phorbol-myristate acetate (PMA,10 ng/mL) and iono-
Med. 189, 1025–1031.
mycin (250 ng/mL) for 12 hr at 37C, 5% CO2. The supernatants were
Balasa, B., Krahl, T., Pastone, G., Lee, J., Tisch, R., McDevitt, H.,assayed for IL-2, IL-4, and IFN- content by ELISA (R&D Systems,
and Sarvetnick, N. (1997). CD40 ligand-CD40 interactions are neces-Minneapolis, MN).
sary for the initiation of insulitis and diabetes in nonobese diabetic
mice. J. Immunol. 159, 4620–4627.Adoptive T Cell Transfer
Bennett, S., Carbone, F., Karamalis, F., Flavell, R., Miller, J., andTo measure the proliferative activity of 8.3-CD8 and 4.1-CD4 T
Heath, W. (1998). Help for cytotoxic T-cell responses is mediatedcells in vivo, splenic 8.3-CD8 or 4.1-CD4 T cells were purified with
by CD40 signalling. Nature 393, 478–480.anti-CD8 or anti-CD4 mAb-coated microbeads (MiniMACS, Miltenyi
Biotec), labeled with CFSE and injected into the tail veins of 8- to Blair, P.J., Riley, J.L., Harlan, D.M., Abe, R., Tadaki, D.K., Hoffmann,
10-week-old NOD hosts (107 cells). Hosts were sacrificed 6 days S.C., White, L., Francomano, T., Perfetto, S.J., Kirk, A.D., and June,
later and their pancreatic and mesenteric lymph nodes examined C.H. (2000). CD40 ligand triggers a short-term CD4() T cell activa-
for presence of CSFE-positive cells and for the levels of CD69 and tion response that results in secretion of immunoupmodulatory cyto-
CD44 on the transfused T cells. To transfer CD4T cells, splenocytes kines and apoptosis. J. Exp. Med. 191, 651–660.
from NOD or NOD.CD154/ mice were depleted of CD8 T cells
Blotta, M., Marshall, J., DeKruyff, R., and Umetsu, D. (1996). Cross-
and B cells or subjected to positive selection with anti-CD4 mAb-
linking of the CD40-ligand on human CD4 T lymphocytes gener-
coated magnetic microbeads. The cells (1.5 
 107 ) were injected
ates a costimulatory signal that up-regulates IL-4 synthesis. J. Im-
into the tail veins of recipient mice, and the mice were followed for
munol. 156, 3133–3140.
diabetes development.
Borrow, P., Tough, D., Eto, D., Tishon, A., Grewal, I., Sprent, J.,
Flavell, R., and Oldstone, M. (1998). CD40 ligand-mediated interac-Agonistic Anti-CD40 mAb and CpG DNA Treatment
tions are involved in the generation of memory CD8 CTL but areAnti-CD40 and anti-B220 mAbs were purified from MAP-tested hy-
not required for the maintenance of CTL memory following virusbridoma culture supernatant by affinity chromatography. Mice re-
infection. J. Virol. 72, 7440–7449.ceived three injections of 100 	g of mAb i.p. or i.v. 3 days apart.
Phosphorothioate-stabilized CpG oligo (TCCATGACGTTCCT Brenner, B., Koppenhoefer, U., Grassme, H., Kun, J., Lang, F., and
GATGCT) was from MWG Biotech (Charlotte, NC). Mice were treated Gulbins, E. (1997). Evidence for a novel function of the CD40 ligand
with one i.p injection of DNA (10 nmoles) and followed for diabetes. as a signaling molecule in T lymphocytes. FEBS Lett. 417, 301–306.
Some mice were injected with CD4 T cells 24 hr after oligodeoxy- Buhlmann, J., Gonzalez, M., Ginther, B., Paniskaltsis-Mortari, A.,
nucleotide treatment. Blazar, B., Greiner, D., Rosini, A., Flavell, R., and Noelle, R. (1999).
Sustained expansion of CD8 T cells requires CD154 expression
Histopathology by Th cells in acute graft versus host disease. J. Immunol. 162,
Pancreata were fixed in formalin, embedded in paraffin, sectioned 4373–4376.
at 4.5 	M, stained with hematoxylin and eosin, and examined for
Caux, C., Massacrier, C., Vanbervliet, B., Dubois, B., Kooten, C.,
inflammation. The degree of insulitis was evaluated by scoring 15–30
Durrand, I., and Banchereau, J. (1994). Activation of human dendritic
islets/mouse using the following criteria: 0, normal islet; 1, peri-
cells through CD40 crosslinking. J. Exp. Med. 180, 1263–1272.
insulitis; 2, mononuclear cell infiltration in 25% of the islet; 3,
Cayabyab, M., Phillips, J., and Lanier, L. (1994). CD40 preferentiallymononuclear cell infiltration in 25%–50% of the islet; 4, 50% of
costimulates activation of CD4 T lymphocytes. J. Immunol. 152,the islet infiltrated.
1523–1531.
Statistical Analyses Cella, M., Scheidegger, D., Palmer-Lehmann, K., Lane, P., Lanzavec-
Data was compared by Mann-Whitney U test or 2. chia, A., and Albert, G. (1996). Ligation of CD40 on dendritic cells
triggers production of high levels of interleukin-12 and enhances
T-cell stimulatory capacity: T-T help via APC activation. J. Exp. Med.Acknowledgments
184, 747–752.
We thank L. Allen, S. Bou, A. Gignac, and M. Deuma for animal care; Christianson, S., Shultz, L., and Leiter, E. (1993). Adoptive transfer
T. Utsugi for providing rIL-2; and Y. Yang for feedback. This work of diabetes into immunodeficient NOD-scid/scid mice. Relative con-
was supported by grants from the Canadian Institutes of Health tributions of CD4 and CD8 T-cells from diabetic versus predia-
Research, the Juvenile Diabetes Research Foundation (JDRF), and betic NOD.NON-thy-1a donors. Diabetes 42, 44–55.
the Canadian Diabetes Association (CDA). P.S. was supported by
Delovitch, T., and Singh, B. (1997). The nonobese diabetic mouse
a studentship from the Alberta Heritage Foundation for Medical
as a model of autoimmune diabetes: immune disregulation gets the
Research (AHFMR), A.A. by fellowships from AHFMR and JDRF,
NOD. Immunity 7, 727–738.
and J.Y. by a fellowship from the CDA. P.S. is a Senior Scholar of
den Haan, J.M., and Bevan, M.J. (2000). A novel helper role for CD4the AHFMR.
T cells. Proc. Natl. Acad. Sci. USA 97, 12950–12952.
Received: October 17, 2001 DiLorenzo, T., Graser, R., Ono, T., Christianson, G., Chapman, H.,
Revised: April 11, 2002 Roopenian, D., Nathenson, S., and Serreze, D. (1998). MHC class
I-restricted T cells are required for all but the end stages of diabetes
development in nonobese diabetic mice and a use prevalent T cellReferences
receptor x chain gene rearrangement. Proc. Natl. Acad. Sci. USA
95, 12538–12543.Amrani, A., Verdaguer, J., Serra, P., Tafuro, S., Tan, R., and Santama-
ria, P. (2000a). Progression of autoimmune diabetes driven by avidity Ding, L., and Shevach, E. (1994). Activation of CD4 T-cells by
maturation of a T-cell population. Nature 406, 739–742. delivery of the B7 costimulatory signal on bystander antigen-pre-
senting cells (trans-costimulation). Eur. J. Immunol. 24, 859–866.Amrani, A., Verdaguer, J., Thiessen, S., Bou, S., and Santamaria, P.
Activation of Diabetogenic CD4 Cells via CD154
731
Green, E., and Flavell, R. (1999). TRANCE-RANK, a new signal path- Moodycliffe, A.M., Shreedhar, V., Ullrich, S.E., Walterscheid, J., Bu-
cana, C., Kripke, M.L., and Flores-Romo, L. (2000). CD40-CD40 li-way involved in lymphocyte development and T cell activation. J.
Exp. Med. 189, 1017–1020. gand interactions in vivo regulate migration of antigen-bearing den-
dritic cells from the skin to draining lymph nodes. J. Exp. Med. 191,Green, E.A., Wong, F.S., Eshima, K., Mora, C., and Flavell, R.A.
2011–2020.(2000). Neonatal tumor necrosis factor alpha promotes diabetes in
nonobese diabetic mice by CD154-independent antigen presenta- Moritani, M., Yoshimoto, K., Li, S., Kondo, M., Iwahana, H., Yamaoka,
tion to CD8() T cells. J. Exp. Med. 191, 225–238. T., Sano, T., Nakano, N., Kikutani, H., and Itakura, M. (1996). Preven-
tion of adoptively transferred diabetes in NOD mice with IL-10-Grewal, I., and Flavell, R. (1998). CD40 and CD154 in cell-mediated
transduced islet-specific Th1 lymphocytes. A gene therapy modelimmunity. Annu. Rev. Immunol. 16, 111–135.
for autoimmune diabetes. J. Clin. Invest. 98, 1851–1859.
Grewal, I., Xu, J., and Flavell, R. (1995). Impairment of antigen-
Nagata, M., Santamaria, P., Kawamura, T., Utsugi, T., and Yoon,specific T-cell priming in mice lacking CD40 ligand. Nature 378,
J.-W. (1994). Evidence for the role of CD8 cytotoxic T cells in the617–620.
destruction of pancreatic beta cells in NOD mice. J. Immunol. 152,
Grewal, I.S., Foellmer, H.G., Grewal, K.D., Xu, J., Hardardottir, F.,
2042–2050.
Baron, J.L., Janeway, C.A., Jr., and Flavell, R.A. (1996). Requirement
Newell, K., He, G., Guo, Z., Kim, O., Szot, G.L., Rulifson, I., Zhou,for CD40 ligand in costimulation induction, T-cell activation, and
P., Hart, J., Thistlethwaite, J.R., and Bluestone, J.A. (1999). Cuttingexperimental allergic encephalomyelitis. Science 273, 1864–1868.
edge: blockade of the CD28/B7 costimulatory pathway inhibits in-
Guerder, S., Picarella, D., Linsley, P., and Flavell, R. (1994). Costimu-
testinal allograft rejection mediated by CD4 but not CD8 T-cells.
lator B7-1 confers antigen-presenting-cell function to parenchymal
J. Immunol. 163, 2358–2362.
tissue and in conjunction with tumor necrosis factor alpha leads to
Peng, X., Kasran, A., Warmerdam, P.A., de Boer, M., and Ceuppens,autoimmunity in transgenic mice. Proc. Natl. Acad. Sci. USA 91,
J.L. (1996). Accessory signaling by CD40 for T cell activation: induc-5138–5142.
tion of Th1 and Th2 cytokines and synergy with interleukin-12 for
Gurunathan, S., Irvine, K., Wu, C., Cohen, J., Thomas, E., Prussin,
interferon-gamma production. Eur. J. Immunol. 26, 1621–1627.
C., Restifo, N., and Seder, R. (1998). CD40 ligand/trimer DNA en-
Renshaw, B.R., Fanslow, W.C., III, Armitage, R.J., Campbell, K.A.,hances both humoral and cellular immune responses and induces
Liggitt, D., Wright, B., Davison, B.L., and Maliszewski, C.R. (1994).protective immunity to infectious and tumor challenge. J. Immunol.
Humoral immune responses in CD40 ligand-deficient mice. J. Exp.161, 4563–4571.
Med. 180, 1889–1900.Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H.,
Ridge, J., Rosa, F.D., and Matzinger, P. (1998). A conditioned den-Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., and Akira, S.
dritic cell can be a temporal bridge between a CD4 T helper and(2000). A Toll-like receptor recognizes bacterial DNA. Nature 408,
a T-killer cell. Nature 393, 474–478.740–745.
Roy, M., Waldschmidt, T., Aruffo, A., Ledbetter, J., and Noelle, R.Hermann, P., Van-Kooten, C., Gaillard, C., Banchereau, J., and
(1993). The regulation of the expression of gp39, the CD4 ligand,Blanchard, D. (1995). CD40 ligand-positive CD8 T cell clones allow
on normal and cloned CD4 T cells. J. Immunol. 151, 2497–2510.B cell growth and differentiation. Eur. J. Immunol. 25, 2972–2977.
Ruedl, C., Kopf, M., and Bachmann, M.F. (1999). CD8() T cellsHoglund, P., Mintern, J., Waltzinger, C., Heath, W., Benoist, C., and
mediate CD40-independent maturation of dendritic cells in vivo. J.Mathis, D. (1999). Initiation of autoimmune diabetes by develop-
Exp. Med. 189, 1875–1884.mentally regulated presentation of islet cell antigens in the pancre-
atic lymph nodes. J. Exp. Med. 189, 331–339. Sad, S., Krishnan, L., Bleakley, R., Kagi, D., Hengartner, H., and
Mossman, T. (1997). Cytotoxicity and weak CD40 ligand expressionKane, L., Lin, J., and Weiss, A. (2000). Signal transduction by the
of CD8 type 2 cytotoxic T-cells restrict their potential B cell helperTCR for antigen. Curr. Opin. Immunol. 12, 242–249.
activity. Eur. J. Immunol. 27, 914–922.Katz, J., Benoist, C., and Mathis, D. (1993). MHC class I molecules
Santamaria, P., Utsugi, T., Park, B., Averill, N., Kawazu, S., and Yoon,are required for the generation of insulitis in non-obese diabetic
J. (1995). Beta cell cytotoxic CD8 T cells from non-obese diabeticmice. Eur. J. Immunol. 23, 3358–3360.
mice use highly homologous T cell receptor alpha chain CDR3 se-Kishimoto, K., Dong, V.M., Issazadeh, S., Fedoseyeva, E.V., Waaga,
quences. J. Immunol. 154, 2494–2503.A.M., Yamada, A., Sho, M., Benichou, G., Auchincloss, H., Jr.,
Schmidt, D., Verdaguer, J., Averill, N., and Santamaria, P. (1997). AGrusby, M.J., et al. (2000). The role of CD154-CD40 versus CD28-
mechanism for the major histocompatibility complex-linked resis-B7 costimulatory pathways in regulating allogeneic Th1 and Th2
tance to autoimmunity. J. Exp. Med. 186, 1059–1075.responses in vivo. J. Clin. Invest. 106, 63–72.
Schoenberger, S.P., Toes, R.E., van der Voort, E.I., Offringa, R.,Koch, F., Stanzl, U., Jennewein, P., Janke, K., Heufler, C., Ka¨mpgen,
and Melief, C.J. (1998). T-cell help for cytotoxic T lymphocytes isE., Romani, N., and Schuler, G. (1996). High level IL-12 production
mediated by CD40-CD40L interactions. Nature 393, 480–483.by murine dendritic cells: upregulation via MHC class II and CD40
molecules and downregulation by IL-4 and IL-10. J. Exp. Med. 184, Schuurhuis, D.H., Laban, S., Toes, R.E., Ricciardi-Castagnoli, P.,
741–746. Kleijmeer, M.J., van der Voort, E.I., Rea, D., Offringa, R., Geuze,
H.J., Melief, C.J., and Ossendorp, F. (2000). Immature dendritic cellsKoppenhoefer, U., Brenner, B., Lang, F., and Gulbins, E. (1997). The
acquire CD8 CTL priming capacity upon activation by T helperCD40-ligand stimulates T lynphocytes via the neural sphingomyelin-
cell-independent or -dependent stimuli. J. Exp. Med. 192, 145–150.ase: a novel function of the CD40-ligand as a signaling molecule.
FEBS Lett. 414, 444–448. Serreze, D., Leiter, E., Christianson, G., Greiner, D., and Roopenian, D.
(1994). Major histocompatibility complex class I-deficient NOD.1mnullLefrancois, L., Olson, S., and Masopust, D. (1999). A critical role for
mice are diabetes and insulitis resistant. Diabetes 43, 505–508.CD40-CD40 ligand interactions in amplification of the mucosal CD8
T cell response. J. Exp. Med. 190, 1275–1284. Shinde, S., Wu, Y., Guo, Y., Niu, Q., Xu, J., Grewal, I., Flavell, R.,
and Liu, Y. (1996). CD40L is important for induction of, but notLu, Z., Yuan, L., Zhou, X., Sotomayor, E., Levitsky, H.I., and Pardoll,
response to, costimulatory activity. ICAM-1 as the second costimu-D.M. (2000). CD40-independent pathways of T cell help for priming
latory molecule rapidly up-regulated by CD40L. J. Immunol. 157,of CD8 CTL. J. Exp. Med. 191, 541–550.
2764–2768.Lutz, M.B., Kukutsch, N., Ogilvie, A.L., Rossner, S., Koch, F., Romani,
Stephens, L., and Kay, T.W.H. (1995). Pancreatic expression of B7N., and Schuler, G. (1999). An advanced culture method for generat-
costimulatory molecules in the non-obese diabetic mouse. Int. Im-ing large quantities of highly pure dendritic cells from mouse bone
munol. 7, 1885–1895.marrow. J. Immunol. Methods 223, 77–92.
Mandelbrot, D.A., Kishimoto, K., Auchincloss, H., Jr., Sharpe, A., Stout, R., and Suttles, J. (1996). The many roles of CD40:CD40L
interactions in cell-mediated imflammatory responses. Immunol. To-and Sayegh, M. (2001). Rejection of mouse cardiac allografts by
costimulation in trans. J. Immunol. 167, 1174–1178. day 17, 487–491.
Immunity
732
Thivolet, C., Bendelac, A., Bedossa, P., Bach, J.-F., and Carnaud,
C. (1991). CD8 T cell homing to the pancreas in the nonobese
diabetic mouse is CD4 T cell-dependent. J. Immunol. 146, 85–88.
Tisch, R., and McDevitt, H. (1996). Insulin-dependent diabetes melli-
tus. Cell 85, 291–297.
Trambley, J., Bingaman, A.W., Lin, A., Elwood, E.T., Waitze, S.Y.,
Ha, J., Durham, M.M., Corbascio, M., Cowan, S.R., Pearson, T.C.,
and Larsen, C.P. (1999). Asialo GM1() and CD8() T cells play a
critical role in costimulation blockade-resistant allograft rejection.
J. Clin. Invest. 104, 1715–1722.
van Essen, D., Kikutani, H., and Gray, D. (1995). CD40 ligand-trans-
duced co-stimulation of T-cells in the development of helper func-
tion. Nature 378, 620–623.
Verdaguer, J., Yoon, J.-W., Anderson, B., Averill, N., Utsugi, T., Park,
B.-J., and Santamaria, P. (1996). Acceleration of spontaneous diabe-
tes in TCR-transgenic NOD mice by beta cell-cytotoxic CD8 T
cells expressing identical endogenous TCR chains. J. Immunol.
157, 4726–4735.
Verdaguer, J., Schmidt, D., Amrani, A., Anderson, B., Averill, N.,
and Santamaria, P. (1997). Spontaneous autoimmune diabetes in
monoclonal T cell nonobese diabetic mice. J. Exp. Med. 186, 1663–
1676.
Wang, B., Gonzalez, A., Benoist, C., and Mathis, D. (1996). The role
of CD8 T-cells in initiation of insulin-dependent diabetes mellitus.
Eur. J. Immunol. 26, 1762–1769.
Whitmire, J., and Ahmed, R. (2000). Costimulation in anti-viral immu-
nity: differential requirements for CD4 and CD8 T cell responses.
Curr. Opin. Immunol. 12, 448–455.
Wicker, L.S., Leiter, E.H., Todd, J.A., Renjilian, R.J., Peterson, E.,
Fischer, P.A., Podolin, P.L., Zijlstra, M., Jaenisch, R., and Peterson,
L.B. (1994). 2-microglobulin-deficient NOD mice do not develop
insulitis or diabetes. Diabetes 43, 500–504.
Wong, F.S., Karttunen, J., Dumont, C., Wen, L., Visintin, I., Pilip, I.M.,
Shastri, N., Pamer, E.G., and Janeway, C.A., Jr. (1999). Identification
of an MHC class I-restricted autoantigen in type 1 diabetes by
screening an organ-specific cDNA library. Nat. Med. 9, 1026–1031.
Yang, Y., and Wilson, J. (1996). CD40 ligand-dependent T-cell activa-
tion: requirement of B7-CD28 signalling through CD40. Science 273,
1862–1865.
